Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BXCL701 in Pancreatic Cancer
NCT04123574Phase 1Withdrawn
- Sponsor
- BioXcel Therapeutics, Inc.
- Start
- Oct 2019
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of talabostat in pancreatic cancer (PC), sponsored by BioXcel Therapeutics, Inc. Primary endpoint: Quantitative and qualitative effects of BXCL701 on immune effector cytokines and cells. Planned start Oct 2019; status: withdrawn.
02
Drugs
talabostat
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT04123574.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04123574.